24809-0

Delete

Print full article

NovaVive’s canine anticancer immunotherapeutic agent to enter clinical trials

The Ontario-based company is teaming up with Iowa State University College of Veterinary Medicine to conduct a clinical study

Suggested Veterinary Products

NovaVive says it is starting clinical trials at Iowa State University (ISU) College of Veterinary Medicine on a new canine anticancer immunotherapeutic.

The anticancer treatment, Immunocidin, has received regulatory approval in Canada and the United States to treat mammary tumours. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who have undergone a splenectomy to determine the effectiveness of Immunocidin in combination with doxorubicin chemotherapy. Sixty-six dogs will participate in the trial and survival times will be monitored.

“Treatment options and survival outcomes for canine HSA have remained essentially stagnant for the past two decades,” said Chad Johannes, DVM, DACVIM (SAIM, oncology). “Additional therapeutic options for HSA are needed and we look forward to learning more about how immune stimulation via Immunocidin may play a role in improving outcomes for dogs.”

Ten U.S. oncology clinics will participate in the trial.

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.